The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Cited by
Sorted by citations
Items 501–600 of 1,002
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 67
Chou, A. P., Chowdhury, R., Li, S., Chen, W., Kim, A. J., Piccioni, D. E., Selfridge, J. M., Mody, R. R., Chang, S., Lalezari, S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs357 · Cited by 67
Hu, J. L., Western, S., & Kesari, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00180 · Cited by 66
Ramakrishnan, V., Xu, B., Akers, J. C., Nguyen, T. P., Ma, J., Dhawan, S., Ning, J., Mao, Y. Q., Hua, W., Kokkoli, E., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102736 · Cited by 68
Linking Metabolic Reprogramming, Plasticity and Tumor Progression
Shuvalov, O., Daks, A., Fedorova, O., Petukhov, A., & Barlev, N. (2021) · Cancers · doi:10.3390/cancers13040762 · Cited by 63
ISG20 promotes local tumor immunity and contributes to poor survival in human glioma
Gao, M., Lin, Y. M., Liu, X., Li, Y., Zhang, C., Wang, Z., Wang, Z., Wang, Y., & Guo, Z. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1534038 · Cited by 63
Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas
Brat, D. J., Aldape, K., Bridge, J. A., Canoll, P., Colman, H., Hameed, M. R., Harris, B. T., Hattab, E. M., Huse, J. T., Jenkins, R. B., et al. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0295-cp · Cited by 69
Self-citationYang, Z., Liu, X., Xu, H., Teschendorff, A. E., Xu, L., Li, J., Fu, M., Liu, J., Zhou, H., Wang, Y., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06488-9 · Cited by 71
DNA Methylation Modifications Associated with Chronic Fatigue Syndrome
de Vega, W. C., Vernon, S. D., & McGowan, P. O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104757 · Cited by 66
Pharmacoepigenetics: an element of personalized therapy?
Majchrzak‐Celińska, A., & Baer‐Dubowska, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1260546 · Cited by 65
Court, F., & Arnaúd, P. (2016) · Oncotarget · doi:10.18632/oncotarget.13746 · Cited by 61
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma
Tiedemann, R. L., Hlady, R. A., Hanavan, P. D., Lake, D. F., Tibes, R., Lee, J., Choi, J.-H., Ho, T. H., & Robertson, K. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6481 · Cited by 66
NOS Expression and NO Function in Glioma and Implications for Patient Therapies
Tran, A. N., Boyd, N., Walker, K. D., & Hjelmeland, A. B. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6820 · Cited by 62
Xiao, D., Huang, J. X., Pan, Y., Li, H. R., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., et al. (2016) · Theranostics · doi:10.7150/thno.17032 · Cited by 62
Sun, X., Johnson, J. L., & John, J. C. S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky339 · Cited by 62
Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
Mirchia, K., & Richardson, T. E. (2020) · Cancers · doi:10.3390/cancers12071817 · Cited by 64
Liu, Z., Yao, Y., Kogiso, M., Zheng, B., Deng, L., Qiu, J. J., Dong, S., Lv, H., Gallo, J. M., Li, X., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500660f · Cited by 60
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma
Williams, M. J., Singleton, W., Lowis, S. P., Malik, K. T. A., & Kurian, K. M. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00045 · Cited by 62
Gilder, A. S., Natali, L., Dyk, D. M. V., Zalfa, C., Banki, M. A., Pizzo, D. P., Wang, H., Klemke, R. L., Mantuano, E., & Gonias, S. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-21358-1 · Cited by 61
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 61
Chatila, W. K., Walch, H. S., Hechtman, J. F., Moyer, S. M., Sgambati, V., Faleck, D. M., Srivastava, A., Tang, L. H., Benhamida, J. K., Ismailgeci, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35592-9 · Cited by 58
Self-citationIDH mutation is associated with higher risk of malignant transformation in low-grade glioma
Leu, S., von Felten, S., Frank, S., Boulay, J., & Mariani, L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2048-y · Cited by 59
Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target
Gargini, R., Segura‐Collar, B., & Sánchez‐Gómez, P. (2020) · Cancers · doi:10.3390/cancers12061622 · Cited by 60
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
Zhang, Y.-A., Zhou, Y., Luo, X., Song, K., Ma, X., Sathe, A. A., Girard, L., Xiao, G., & Gazdar, A. F. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.040 · Cited by 58
Mesenchymal Transformation: The Rosetta Stone of Glioblastoma Pathogenesis and Therapy Resistance
Azam, Z., To, S. S. T., & Tannous, B. A. (2020) · Advanced Science · doi:10.1002/advs.202002015 · Cited by 62
DNA methylation profiling for molecular classification of adult diffuse lower-grade gliomas
Vega, S. F., Bontell, T. O., Corell, A., Smits, A., Jakola, A. S., & Carén, H. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01085-7 · Cited by 59
Venneti, S., Felicella, M. M., Coyne, T. M., Phillips, J. J., Gorovets, D. J., Huse, J. T., Kofler, J., Lü, C., Tihan, T., Sullivan, L. M., et al. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182898113 · Cited by 61
Self-citationIntegrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations
Roy, D. M., Walsh, L. A., Desrichard, A., Huse, J. T., Wu, W., Gao, J., Bose, P., Lee, W., & Chan, T. A.-T. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.025 · Cited by 58
Self-citationSchlosberg, C., VanderKraats, N. D., & Edwards, J. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx078 · Cited by 52
Matteo, D. A., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A. D., & Sohl, C. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776179 · Cited by 62
Reciprocal Regulation of Metabolic Reprogramming and Epigenetic Modifications in Cancer
Yu, X., Ma, R., Wu, Y., Zhai, Y., & Li, S. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00394 · Cited by 64
The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas
Reiter–Brennan, C., Semmler, L., & Klein, A. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.82642 · Cited by 57
Krautkramer, K. A., Dhillon, R. S., Denu, J. M., & Carey, H. V. (2017) · Translational research · doi:10.1016/j.trsl.2017.08.005 · Cited by 61
Rapid intraoperative molecular genetic classification of gliomas using Raman spectroscopy
Livermore, L. J., Isabelle, M., Bell, I. M., Scott, C., Walsby-Tickle, J., Gannon, J. M., Plaha, P., Vallance, C., & Ansorge, O. (2019) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdz008 · Cited by 62
DNA methylation changes in epithelial ovarian cancer histotypes
Earp, M. A., & Cunningham, J. M. (2015) · Genomics · doi:10.1016/j.ygeno.2015.09.001 · Cited by 58
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
Dunn, G. P., Andronesi, O. C., & Cahill, D. P. (2013) · Neurosurgical FOCUS · doi:10.3171/2012.12.focus12355 · Cited by 59
Stefano, A. L. D., Enciso-Mora, V., Marie, Y., Desestret, V., Labussière, M., Boisselier, B., Mokhtari, K., Idbaïh, A., Hoang‐Xuan, K., Delattre, J., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos284 · Cited by 58
Navis, A. C., Niclou, S. P., Fack, F., Stieber, D., van Lith, S. A. M., Verrijp, K. N., Wright, A. J., Stauber, J., Tops, B. B. J., Otte‐Höller, I., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-18 · Cited by 61
IDH1/2 mutation detection in gliomas
Arita, H., Narita, Y., Yoshida, A., Hashimoto, N., Yoshimine, T., & Ichimura, K. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0197-x · Cited by 58
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 63
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Nie, E., Miao, F., Jin, X., Wu, W., Zhou, X., Zeng, A., Yu, T., Zhi, T., Shi, Z., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0596-2 · Cited by 58
Chen, Y.-C., Gotea, V., Margolin, G., & Elnitski, L. L. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005840 · Cited by 56
Progress in the application of molecular biomarkers in gliomas
Wang, J., Su, H.-K., Zhao, H., Chen, Z.-P., & To, S. S. T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.148 · Cited by 59
Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients
Kanamori, M., Higa, T., Sonoda, Y., Murakami, S., Dodo, M., Kitamura, H., Taguchi, K., Shibata, T., Watanabe, M., Suzuki, H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou282 · Cited by 57
Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma
Agnihotri, S., Aldape, K., & Zadeh, G. M. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14505 · Cited by 59
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 63
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
Kinslow, C. J., Mercurio, A. C., Kumar, P., Rae, A. I., Siegelin, M. D., Grinband, J., Taparra, K., Upadhyayula, P. S., McKhann, G. M., Sisti, M. B., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0990 · Cited by 56
Metabolic Modulation of Epigenetics in Gliomas
Venneti, S., & Thompson, C. B. (2013) · Brain Pathology · doi:10.1111/bpa.12022 · Cited by 56
Self-citationMa, S., Jiang, B., Deng, W., Gu, Z.-K., Wu, F.-Z., Li, T., Xia, Y., Yang, H., Ye, D., Xiong, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3330 · Cited by 57
Simeonova, I., & Huillard, E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1675-3 · Cited by 59
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 55
Ohba, S., Mukherjee, J., Johannessen, T.-C. A., Mancini, A., Chow, T. T., Wood, M. D., Jones, L. E., Mazor, T., Marshall, R. E., Viswanath, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0696 · Cited by 55
Epigenetic determinants of metastasis
Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 58
Liao, P., Ostrom, Q. T., Stetson, L. C., & Barnholtz‐Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy003 · Cited by 54
BCL3 expression promotes resistance to alkylating chemotherapy in gliomas
Wu, L., Bernal, G. M., Cahill, K. E., Pytel, P., Fitzpatrick, C. A., Mashek, H., Weichselbaum, R. R., & Yamini, B. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar2238 · Cited by 56
Decoding the Rosetta stone of mitonuclear communication
English, J., Son, J. M., Cardamone, M. D., Lee, C., & Perissi, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105161 · Cited by 55
The Network Zoo: a multilingual package for the inference and analysis of gene regulatory networks
Guebila, M. B., Wang, T., Lopes‐Ramos, C. M., Fanfani, V., Weighill, D., Burkholz, R., Schlauch, D., Paulson, J. N., Altenbuchinger, M., Shutta, K. H., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02877-1 · Cited by 55
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
Wu, R., Sun, C., Chen, X., Yang, R., Luan, Y., Zhao, X., Yu, P., Luo, R., Hou, Y., Tian, R., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321611121 · Cited by 56
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 57
Application of Metabolomics in Drug Resistant Breast Cancer Research
Shajahan‐Haq, A. N., Cheema, M., & Clarke, R. C. (2015) · Metabolites · doi:10.3390/metabo5010100 · Cited by 56
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma
Šamec, N., Zottel, A., Paska, A. V., & Jovčevska, I. (2020) · Molecules · doi:10.3390/molecules25030490 · Cited by 55
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation
Hansen, L. J., Sun, R., Yang, R. R., Singh, S. X., Chen, L. H., Pirozzi, C. J., Moure, C. J., Hemphill, C., Carpenter, A. B., Healy, P. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1010 · Cited by 56
Fordham, A.-J., Craft-Hacherl, C., Patel, N., Jones, K., Myers, B., Abraham, M. E., & Gendreau, J. L. (2021) · Cancers · doi:10.3390/cancers13122960 · Cited by 55
Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma
Morokoff, A. P., Ng, W., Gogos, A., & Kaye, A. H. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.02.008 · Cited by 55
Mur, P., Mollejo, M., Ruano, Y., de Lope, Á. R., Fiaño, C., García, J. F., Castresana, J. S., Hernández‐Laín, A., REY, J. A., & Meléndez, B. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1130-9 · Cited by 54
Antagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 54
Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification
Olar, A., & Sulman, E. P. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.006 · Cited by 56
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 54
Favero, F., McGranahan, N., Salm, M. P., Birkbak, N. J., Sanborn, Z., Benz, S. C., Becq, J., Peden, J. F., Kingsbury, Z., Grocock, R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv127 · Cited by 56
The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma
Carén, H., Pollard, S. M., & Beck, S. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.007 · Cited by 55
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 56
The degree of mitochondrial DNA methylation in tumor models of glioblastoma and osteosarcoma
Sun, X., Vaghjiani, V., Jayasekara, W. S. N., Cain, J. E., & John, J. C. S. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0590-0 · Cited by 54
Metabolic regulation of prostate cancer heterogeneity and plasticity
Peitzsch, C., Gorodetska, I., Klusa, D., Shi, Q., Alves, T. C., Pantel, K., & Dubrovska, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.002 · Cited by 54
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
Chan, T. A.-T., Ho, A. S., & Turcan, Ş. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34680 · Cited by 54
Self-citationThe role of mitochondria in the oncogenic signal transduction
Frezza, C. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.12.013 · Cited by 53
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical ImplicationsPreprint
Yegnasubramanian, S., Marzo, A. M. D., & Nelson, W. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030445 · Cited by 53
LDL receptors and their role in targeted therapy for glioma: a review
Pawar, S., Koneru, T., McCord, E., Tatiparti, K., Sau, S., & Iyer, A. K. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.008 · Cited by 56
Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma
Chai, P., Jia, R., Li, Y., Zhou, C., Gu, X., Yang, L., Shi, H., Tian, H., Lin, H., Yu, J., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101030 · Cited by 56
Acute lymphoblastic leukemia displays a distinct highly methylated genome
Hetzel, S., Mattei, A. L., Kretzmer, H., Qu, C., Chen, X. '., Fan, Y., Wu, G., Roberts, K. G., Luger, S. M., Litzow, M. R., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00370-5 · Cited by 52
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Mariani, C. J., Madžo, J., Moen, E. L., Yesilkanal, A. E., & Godley, L. A. (2013) · Cancers · doi:10.3390/cancers5030786 · Cited by 53
Montemurro, N. (2019) · Journal of Neurological Surgery Part A Central European Neurosurgery · doi:10.1055/s-0039-1688911 · Cited by 53
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
The Role of Gene Body Cytosine Modifications in MGMT Expression and Sensitivity to Temozolomide
Moen, E. L., Stark, A. L., Zhang, W., Dolan, M. E., & Godley, L. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0924 · Cited by 51
Ichimura, N., Shinjo, K., An, B., Shimizu, Y., Yamao, K., Ohka, F., Katsushima, K., Hatanaka, A., Tojo, M., Yamamoto, E., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0306 · Cited by 55
Levell, J. R., Caferro, T. R., Chenail, G., Dix, I., Dooley, J., Firestone, B., Fortin, P. D., Giraldes, J., Gould, T. A., Growney, J. D., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00334 · Cited by 51
IDH mutation-specific radiomic signature in lower-grade gliomas
Liu, X., Li, Y., Li, S., Fan, X., Sun, Z., Yang, Z., Wang, K., Zhang, Z., Jiang, T., Liu, Y., et al. (2019) · Aging · doi:10.18632/aging.101769 · Cited by 51
Developmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 55
Targeting Cell Metabolism as Cancer Therapy
Ngoi, N. Y. L., Eu, J. Q., Hirpara, J. L., Wang, L., Lim, J. S. J., Lee, S. C., Lim, Y., Pervaiz, S., Goh, B. C., & Wong, A. L. A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7947 · Cited by 52
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
Bledea, R., Vasudevaraja, V., Patel, S. V., Stafford, J. M., Serrano, J., Esposito, G., Tredwin, L. M., Goodman, N. E., Kloetgen, A., Golfinos, J. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53262-7 · Cited by 52
Molecular predictors of outcome in low-grade glioma
Weiler, M., & Wick, W. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32835a0217 · Cited by 50
Roles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 52
Concepts in glioma immunotherapy
Platten, M., Bunse, L., Wick, W., & Bunse, T. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1874-x · Cited by 50
Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults
Rodríguez, F. J., Vizcaíno, M. A., & Lin, M. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.05.005 · Cited by 50
Nutrient Exploitation within the Tumor–Stroma Metabolic Crosstalk
Morandi, A., Giannoni, E., & Chiarugi, P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.001 · Cited by 50
Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
Hsieh, K. L., Chen, C., & Lo, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17585 · Cited by 50
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
